Devyser Diagnostics (DVYSR) Life Science Conference 2026 summary

Growth and financial performance

• Achieved over 3.5 million tests sold to date, with gross margin exceeding 80%.

• Revenue has grown at a 33% CAGR, reaching MSEK 216.9 in 2023.

• EBIT target set at over 25% by Q4 2025.

• Expanded product portfolio to over 30 products and workforce to more than 115 employees.

• Operations now cover more than 65 countries.

Strategic focus and partnerships

• Aims to be the premier partner for all clinical genetics labs and transplantation labs.

• Focuses on decentralizing transplant diagnostics to improve patient outcomes.

• Product lines include hereditary cancer, reproductive health, cystic fibrosis, cardiovascular diseases, and hematology.

• Utilizes both direct sales and distributor channels for market reach.

• Partnerships and acquisitions, such as Cybergene AB, support strategic growth.

Product innovation and workflow improvements

• Solutions simplify lab workflows, reducing hands-on time to under 45 minutes.

• Achieves test turnaround times of 2–3 days, enhancing speed and reliability.

• Minimizes risk of sample mix-up, improving safety.

• Decentralized testing model offers faster results and higher performance compared to centralized alternatives.

• Recent launches include Thalassemia v2 IVDR.